Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf

Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf

ID:34241036

大小:1.48 MB

页数:6页

时间:2019-03-04

Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf_第1页
Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf_第2页
Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf_第3页
Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf_第4页
Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf_第5页
资源描述:

《Narrowing the gap between clinical capsule formulations and commercial film coated tablets.pdf》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、Narrowingthegapbetweenclinicalcapsuleformulationsandcommercialfilm-coatedtabletsBasedonformulationsimplicityandblindingcapability,hardgelatincapsulesarepreferrablecomparedwithotheroralsoliddosageforms,includingtablets,intheearlyclinicalphasesofdrugdevelopment.However,asa

2、resultofeconomicandothermarketingconsiderations,mostoralsoliddosageformsonthemarkettodayaretablets.Theauthorssuggestthattimecouldbesavedinformulationdevelopmentifrelativelysimple,commonformulations,suitableforuseinbothcapsuleandtabletdosageforms,canbedevelopedintheprecli

3、nicalphase.Fourcasestudies,withformulaecontainingmodeldrugsofvaryingdoseandwatersolubility,weredevelopedtoillustratetheconcept.Ineachcase,comparativedissolutionprofilesofcapsulesandcorrespondinguncoatedandfilm-coatedtabletsshowedequivalencein vitro.NgocDoThegoalofearlycl

4、inicaltrialsistoestablishWhilehardgelatincapsuleformulationsforJasonHansellthesafetyandproof-of-conceptefficacyearly-phasestudieshavemanydesirablefeatures,ThomasP.FarrellofanewAPI.1LimitedamountsoftheAPIandtheyarenotcommerciallyviablemostofthetime.3,4PEERColorconInc.REVI

5、EWEDaggressivedevelopmenttimelines,however,oftenThereasonforthisisthatthemanufactureofearlyforceformulatorstodevelopsimplehardgelatinclinicalformulationscannotusuallybetransferredtoPEERcapsuleformulationsforearly-phaseclinicallarge-scaleproductionequipmentand,assuch,theR

6、EVIEWEDuse;2thecompositionofwhichcouldbetheAPIdevelopmentofaseconddrugproductforlate-phasealone,orasimplepowderblendoftheAPIandclinicalstudiesthatcanbemanufacturedonaafiller.Notonlyaretheyusefulforsimplifyinglarge-scaleandischemicallycompatible,stableandformulations,hard

7、gelatincapsulesarealsousefulbioavailable,isnecessary.Basedoneconomicandformaskingthetasteandodouroftheactivecertainmarketingconsiderations,tabletsaremostblendaswellasforblindingmarketedproducts.oftenformulatedforlate-stageclinicaltrialsandThepositivecomparatorscaneasilyb

8、eblindedascommercialization;theyaremoretamper-resistanttablets-in-capsulesorcapsule-in-capsules.thanhar

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。